Move oncology innovation forward and bring new treatments to patients
IQVIA helps you deliver new ways to bring cures to market for the patients who rely on them most. Tap into areas of expertise such as biomarker discovery and analysis, precision medicine, immuno-oncology, market access, regulatory, pediatric oncology, adoptive cell offering, and novel delivery scenarios.
- Unparalleled institutional knowledge. Our Oncology Center of Excellence can help shepherd your molecule from early clinical development through commercialization. We assist in unique Oncology planning and design scenarios through collaboration with our Rare Disease and Biosimilar Centers of Excellence, and our focus on companion diagnostics and incorporation of ground-breaking biomarker methodology.
- More efficient oncology trials. The IQVIA CORE™ brings the promise of faster times to study endpoints, fewer protocol amendments, and accelerated time to market. In the world of personalized medicine, our proprietary Precision Enrollment approach – based on biomarker testing – identifies patients eligible for studies in advance of site identification, optimizing recruitment and screen failure rates.
- Pave a predictable path forward. Leverage real-world site and non-identified patient-level data leads to more precisely select the best sites for faster enrollment of the right patients. You gain a reality-based and predictable study plan that increases your chances of success.
- Agile to your needs, always. With the growing complexity of novel compounds and treatment combinations, we quickly respond to changing market dynamics and new scientific discoveries. We recognize the special needs of the emerging biopharma industry and early oncology clinical development, and deliver flexible, high-touch services, peer-to-peer medical contact and competitive pricing.
You need data, insights, technology and human intelligence to reimagine a new path forward for cancer care. We are here to help make that possible.
Let us help you develop and deliver your oncology treatment successfully.
By: Forrest Anthony
By: Forrest Anthony
By: Brad Smith